GlobeNewswire Inc.··Boundless BioBoundless Bio Touts First-in-Class Breast Cancer Drug as AACR Data Bolsters Rare DNA Target
Boundless Bio presented preclinical data for BBI-940, an oral kinesin degrader targeting extrachromosomal DNA in breast cancer, with Phase 1 trials underway.
BOLDbreast cancerPhase 1 clinical trial